117 related articles for article (PubMed ID: 1971090)
1. Xbal 16- plus 9-kilobase DNA restriction fragments identify a mutant allele for debrisoquin hydroxylase: report of a family study.
Evans WE; Relling MV
Mol Pharmacol; 1990 May; 37(5):639-42. PubMed ID: 1971090
[TBL] [Abstract][Full Text] [Related]
2. Debrisoquine oxidation polymorphism: phenotypic consequences of a 3-base-pair deletion in exon 5 of the CYP2D6 gene.
Broly F; Meyer UA
Pharmacogenetics; 1993 Jun; 3(3):123-30. PubMed ID: 8101460
[TBL] [Abstract][Full Text] [Related]
3. Frequent distribution of ultrarapid metabolizers of debrisoquine in an ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles.
Aklillu E; Persson I; Bertilsson L; Johansson I; Rodrigues F; Ingelman-Sundberg M
J Pharmacol Exp Ther; 1996 Jul; 278(1):441-6. PubMed ID: 8764380
[TBL] [Abstract][Full Text] [Related]
4. Concordance of P450 2D6 (debrisoquine hydroxylase) phenotype and genotype: inability of dextromethorphan metabolic ratio to discriminate reliably heterozygous and homozygous extensive metabolizers.
Evans WE; Relling MV
Pharmacogenetics; 1991 Dec; 1(3):143-8. PubMed ID: 1688245
[TBL] [Abstract][Full Text] [Related]
5. Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population.
Dahl ML; Johansson I; Palmertz MP; Ingelman-Sundberg M; Sjöqvist F
Clin Pharmacol Ther; 1992 Jan; 51(1):12-7. PubMed ID: 1346258
[TBL] [Abstract][Full Text] [Related]
6. Debrisoquine polymorphism: novel CYP2D6 gene Bam HI restriction fragment length polymorphism in the Ngawbé Guaymí Indian of Panama.
Petersen DD; Kong AN; Jorge LF; Nebert DW; Arias TD
Pharmacogenetics; 1991 Dec; 1(3):136-42. PubMed ID: 1688244
[TBL] [Abstract][Full Text] [Related]
7. Human debrisoquine hydroxylase gene polymorphisms in cancer patients and controls.
Sugimura H; Caporaso NE; Shaw GL; Modali RV; Gonzalez FJ; Hoover RN; Resau JH; Trump BF; Weston A; Harris CC
Carcinogenesis; 1990 Sep; 11(9):1527-30. PubMed ID: 1976046
[TBL] [Abstract][Full Text] [Related]
8. Two mutant alleles of the human cytochrome P-450db1 gene (P450C2D1) associated with genetically deficient metabolism of debrisoquine and other drugs.
Skoda RC; Gonzalez FJ; Demierre A; Meyer UA
Proc Natl Acad Sci U S A; 1988 Jul; 85(14):5240-3. PubMed ID: 2899325
[TBL] [Abstract][Full Text] [Related]
9. Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine. Study of the functional significance of individual mutations by expression of chimeric genes.
Kagimoto M; Heim M; Kagimoto K; Zeugin T; Meyer UA
J Biol Chem; 1990 Oct; 265(28):17209-14. PubMed ID: 2211621
[TBL] [Abstract][Full Text] [Related]
10. Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis.
Dahl ML; Johansson I; Bertilsson L; Ingelman-Sundberg M; Sjöqvist F
J Pharmacol Exp Ther; 1995 Jul; 274(1):516-20. PubMed ID: 7616439
[TBL] [Abstract][Full Text] [Related]
11. Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population.
Broly F; Gaedigk A; Heim M; Eichelbaum M; Morike K; Meyer UA
DNA Cell Biol; 1991 Oct; 10(8):545-58. PubMed ID: 1681816
[TBL] [Abstract][Full Text] [Related]
12. 1462V mutation in the human CYP1A1 gene: lack of correlation with either the Msp I 1.9 kb (M2) allele or CYP1A1 inducibility in a three-generation family of east Mediterranean descent.
Wedlund PJ; Kimura S; Gonzalez FJ; Nebert DW
Pharmacogenetics; 1994 Feb; 4(1):21-6. PubMed ID: 7516235
[TBL] [Abstract][Full Text] [Related]
13. Association of a 12.5-kilobase allele of the MspI restriction fragment length polymorphism of the C6 gene in patients with total deficiency of the sixth component of complement.
Potter PC; Warburton C; Würzner R; Orren A; Di Scipio R
Exp Clin Immunogenet; 1993; 10(1):38-44. PubMed ID: 7691111
[TBL] [Abstract][Full Text] [Related]
14. Genetic and metabolic criteria for the assignment of debrisoquine 4-hydroxylation (cytochrome P4502D6) phenotypes.
Daly AK; Armstrong M; Monkman SC; Idle ME; Idle JR
Pharmacogenetics; 1991 Oct; 1(1):33-41. PubMed ID: 1688241
[TBL] [Abstract][Full Text] [Related]
15. A new CYP2A6 gene deletion responsible for the in vivo polymorphic metabolism of (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride in humans.
Nunoya KI; Yokoi T; Kimura K; Kainuma T; Satoh K; Kinoshita M; Kamataki T
J Pharmacol Exp Ther; 1999 Apr; 289(1):437-42. PubMed ID: 10087035
[TBL] [Abstract][Full Text] [Related]
16. Carrier detection in severe (type III) von Willebrand disease using two intragenic restriction fragment length polymorphisms.
Bahnak BR; Lavergne JM; Verweij CL; Rothschild C; Pannekoek H; Larrieu MJ; Meyer D
Thromb Haemost; 1988 Oct; 60(2):178-81. PubMed ID: 2905841
[TBL] [Abstract][Full Text] [Related]
17. Analysis of the CYP2D6 gene mutations and their consequences for enzyme function in a West African population.
Griese EU; Asante-Poku S; Ofori-Adjei D; Mikus G; Eichelbaum M
Pharmacogenetics; 1999 Dec; 9(6):715-23. PubMed ID: 10634134
[TBL] [Abstract][Full Text] [Related]
18. Debrisoquine hydroxylase and Parkinson's disease.
Kondo I; Kanazawa I
Adv Neurol; 1993; 60():338-42. PubMed ID: 8420147
[TBL] [Abstract][Full Text] [Related]
19. Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology.
Steen VM; Andreassen OA; Daly AK; Tefre T; Børresen AL; Idle JR; Gulbrandsen AK
Pharmacogenetics; 1995 Aug; 5(4):215-23. PubMed ID: 8528268
[TBL] [Abstract][Full Text] [Related]
20. Prediction of phenotype for dextromethorphan O-demethylation by using polymerase chain reaction in healthy volunteers.
Zimmermann T; Schlenk R; Pfaff G; Lach P; Wildfeuer A
Arzneimittelforschung; 1995 Jan; 45(1):41-3. PubMed ID: 7893267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]